{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T05:13:12Z","timestamp":1771564392019,"version":"3.50.1"},"reference-count":29,"publisher":"BMJ","issue":"2","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2019,2,9]]},"published-print":{"date-parts":[[2019,2]]},"abstract":"<jats:p>A 46-year-old man presented with a 4-week history of bruising with subcutaneous nodules and weight loss. He also had a 2-week history of progressive back and hip pain. He had been diagnosed with stage Ib cutaneous melanoma 30 months previously, which had been fully excised. A sentinel lymph node biopsy was negative. On examination, there were five skin lesions at different stages. Each had spontaneously appeared as a bruise with a central subcutaneous nodule, and the bruising then faded to leave a persistent subcutaneous nodule. Excision of one of the nodules demonstrated a 4.5\u2009mm diameter partly necrotic melanoma deposit in the dermis. CT scan of the head, chest, abdomen and pelvis showed widespread metastases. This rare presentation of cutaneous malignant melanoma metastases has been termed \u2018sentinel bruising\u2019. There are fewer than 10 cases reported in the literature.<\/jats:p>","DOI":"10.1136\/bcr-2018-228114","type":"journal-article","created":{"date-parts":[[2019,2,25]],"date-time":"2019-02-25T13:59:16Z","timestamp":1551103156000},"page":"e228114","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Sentinel bruising as a presentation of metastatic melanoma"],"prefix":"10.1136","volume":"12","author":[{"given":"Lloyd","family":"Steele","sequence":"first","affiliation":[{"name":"Imperial College Healthcare NHS Trust, London, UK"},{"name":"Acute Medicine, Portsmouth Hospitals NHS Trust, Portsmouth, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chit Cheng","family":"Yeoh","sequence":"additional","affiliation":[{"name":"Medical Oncology, Portsmouth Hospitals NHS Trust, Portsmouth, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2019,2,25]]},"reference":[{"key":"2025082803060689000_12.2.e228114.1","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ejcsup.2013.07.012","article-title":"Melanoma epidemiology, biology and prognosis","volume":"11","author":"Ali","year":"2013","journal-title":"EJC Suppl"},{"key":"2025082803060689000_12.2.e228114.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.12.027"},{"key":"2025082803060689000_12.2.e228114.3","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdp252"},{"key":"2025082803060689000_12.2.e228114.4","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/pcmr.12544","article-title":"Metastatic pathways in patients with cutaneous melanoma","volume":"30","author":"Adler","year":"2017","journal-title":"Pigment Cell Melanoma Res"},{"key":"2025082803060689000_12.2.e228114.5","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/ijd.12346","article-title":"Dermoscopic patterns of cutaneous melanoma metastases","volume":"53","author":"Rubegni","year":"2014","journal-title":"Int J Dermatol"},{"key":"2025082803060689000_12.2.e228114.6","doi-asserted-by":"publisher","DOI":"10.1097\/00008390-200410000-00006"},{"key":"2025082803060689000_12.2.e228114.7","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S1470-2045(15)00087-X","article-title":"Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial","volume":"16","author":"Grob","year":"2015","journal-title":"Lancet Oncol"},{"key":"2025082803060689000_12.2.e228114.8","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1093\/annonc\/mdx176","article-title":"Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E\/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study","volume":"28","author":"Long","year":"2017","journal-title":"Ann Oncol"},{"key":"2025082803060689000_12.2.e228114.9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31601-X"},{"key":"2025082803060689000_12.2.e228114.10","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/S1470-2045(18)30700-9","article-title":"Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial","volume":"19","author":"Hodi","year":"2018","journal-title":"Lancet Oncol"},{"key":"2025082803060689000_12.2.e228114.11","unstructured":"Sharp M , Corp D . Study to Evaluate the safety and efficacy of two different dosing schedules of pembrolizumab (MK-3475) compared to ipilimumab in participants with advanced melanoma (mk-3475-006\/keynote-006). secondary study to evaluate the safety and efficacy of two different dosing schedules of pembrolizumab (MK-3475) Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006\/KEYNOTE-006). 2013 https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01866319 (Accessed 10 Oct 2018)."},{"key":"2025082803060689000_12.2.e228114.12","unstructured":"Bristol-Myers Squibb. Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic Melanoma (CheckMate 069). Secondary Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic Melanoma (CheckMate 069). 2013 https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01927419 (Accessed 10 Oct 2018)."},{"key":"2025082803060689000_12.2.e228114.13","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/S0007-1226(03)00373-4","article-title":"Metastatic malignant melanoma presenting with a bruise","volume":"56","author":"Connolly","year":"2003","journal-title":"Br J Plast Surg"},{"key":"2025082803060689000_12.2.e228114.14","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(03)00463-8"},{"key":"2025082803060689000_12.2.e228114.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.bjps.2004.06.012"},{"key":"2025082803060689000_12.2.e228114.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2005.10.023"},{"key":"2025082803060689000_12.2.e228114.17","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.144.4.561"},{"key":"2025082803060689000_12.2.e228114.18","doi-asserted-by":"crossref","first-page":"56","DOI":"10.4081\/dr.2011.e56","article-title":"Resolution of Cullen\u2019s sign in patient with metastatic melanoma responding to hypoxia-activated prodrug TH-302","volume":"3","author":"Weiss","year":"2011","journal-title":"Dermatology Reports"},{"key":"2025082803060689000_12.2.e228114.19","first-page":"409","article-title":"Multiple haemorrhagic-like cutaneous metastasis of malignant melanoma","volume":"15","author":"Dereure","year":"2005","journal-title":"Eur J Dermatol"},{"key":"2025082803060689000_12.2.e228114.20","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/CMR.0b013e32832eabb5","article-title":"Hemorrhagic regression of melanoma metastases during therapeutic vaccination: a report of three cases","volume":"19","author":"Pierret","year":"2009","journal-title":"Melanoma Res"},{"key":"2025082803060689000_12.2.e228114.21","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1111\/ced.13667","article-title":"Cutaneous metastases of melanoma presenting as sudden haematomas: clinical, dermoscopic and sonographic features","volume":"43","author":"\u00c1lvarez-Chinchilla","year":"2018","journal-title":"Clin Exp Dermatol"},{"key":"2025082803060689000_12.2.e228114.22","doi-asserted-by":"crossref","first-page":"e90","DOI":"10.1016\/j.bjps.2008.08.051","article-title":"Sentinel bruising in metastatic malignant melanoma","volume":"63","author":"Paton","year":"2010","journal-title":"J Plast Reconstr Aesthet Surg"},{"key":"2025082803060689000_12.2.e228114.23","first-page":"472","article-title":"Melanoma staging: evidence-based changes in the american joint committee on cancer eighth edition cancer staging manual","volume":"67","author":"Gershenwald","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"2025082803060689000_12.2.e228114.24","first-page":"318","article-title":"Metastatic patterns, clinical outcome, and malignant phenotype in malignant cutaneous melanoma","volume":"38","author":"Cohn-Cedermark","year":"1999","journal-title":"Acta Oncol"},{"key":"2025082803060689000_12.2.e228114.25","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2002.04867.x"},{"key":"2025082803060689000_12.2.e228114.26","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdm498"},{"key":"2025082803060689000_12.2.e228114.27","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.jaad.2016.11.051","article-title":"Identification of high-risk cutaneous melanoma tumors is improved when combining the online american joint committee on cancer individualized melanoma patient outcome prediction tool with a 31-gene expression profile-based classification","volume":"76","author":"Ferris","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"2025082803060689000_12.2.e228114.28","doi-asserted-by":"publisher","DOI":"10.1038\/nature17038"},{"key":"2025082803060689000_12.2.e228114.29","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/bjd.16347","article-title":"A new era of proactive melanoma therapy: hit hard, hit early","volume":"178","author":"Haas","year":"2018","journal-title":"Br J Dermatol"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2018-228114","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T10:06:16Z","timestamp":1756375576000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2018-228114"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":29,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,2,25]]},"published-print":{"date-parts":[[2019,2]]}},"alternative-id":["10.1136\/bcr-2018-228114"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2018-228114","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2]]}}}